Nash Videos

▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.

NASH 2024: The New Nomenclature and Revised Definition

Dive into the transformative world of liver health with Prof. Vlad Ratziu's enlightening insights on the latest nomenclature and definitions for steatotic liver disease. Discover why the medical community is adopting a new, inclusive language for Non-Alcoholic Fatty Liver Disease (NAFLD), now redefined to reflect its complex interplay with metabolic dysfunction and lifestyle factors.
View More ⏩NASH 2024: The New Nomenclature and Revised Definition

Clinical Chemistry In NAFLD Part 3 – Biomarkers and Hepatic Fibrosis

Discover the intricate dynamics of Clinical Chemistry in NAFLD with Dr. Guillaume Grzych, a leading expert in medical biology and advanced computational techniques. Dive deep into the pathophysiology of liver fibrosis, explore the potential of biomarkers, and understand diagnostic tools like the AST-to-ALT ratio, FibroTest, APRI, FIB-4, and the ELF Score.
View More ⏩Clinical Chemistry In NAFLD Part 3 – Biomarkers and Hepatic Fibrosis
Clinical Chemistry in NAFLD Part 2 – Biomarkers and Hepatic Steatosis and NASH

Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH

Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and management. Delve into the disease's pathophysiology, the impact of obesity and insulin resistance, and the advancements in specialized liver tests.
View More ⏩Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH

Clinical Chemistry in NAFLD Part 1 – Interest and Why?

Explore the complexities of NAFLD (Non-Alcoholic Fatty Liver Disease), now also known as MAFLD, and its evolving terminology, diagnostic challenges, and association with cardio-metabolic syndrome. Learn about its progressive nature, the gold standard for diagnosis, and the emerging role of biomarkers. A must-read for healthcare professionals aiming for early diagnosis and effective management.
View More ⏩Clinical Chemistry in NAFLD Part 1 – Interest and Why?
NAFLD Pathophysiologic Role of Intrahepatic Vasculature

NAFLD Pathophysiologic Role of Intrahepatic Vasculature

Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions that portal hypertension is present in patients with NAFLD and can be evident in the early stages which is caused by intrahepatic vascular alterations. Further, he explores the different types of drugs that will help change the course of the disease.
View More ⏩NAFLD Pathophysiologic Role of Intrahepatic Vasculature

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES